Promising Biomarkers in Renal Cell Carcinoma

Author:

Kapoor Jada1,Claps Francesco2,Mir M. Carmen3,Ischia Joseph1

Affiliation:

1. Department of Urology, Austin Health, Melbourne, Australia

2. Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain

3. Department of Urology, University of Trieste, Hospital of Cattinara, Trieste, Italy

Abstract

Renal cell carcinoma (RCC) incidence has been increasing in recent years, and it now represents the sixth most common cancer diagnosis in men and the tenth in women. Although this is partly due to in-creased detection of incidental small renal masses on unrelated imaging, advanced RCC continues to be diagnosed in a significant portion of patients, with more than 15% presenting with distant metasta-ses. Biomarkers can be a cost-effective tool to identify high-risk patients and institute appropriate indi-vidualised therapies. While the literature in this field is nascent, this paper focuses on several bi-omarkers that have been extensively investigated in the diagnosis and prognosis of RCC, as well as in predicting its response to treatments, particularly the newer immuno-oncology drugs.

Publisher

Societe Internationale dUrologie

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Lipids as Targets for Renal Cell Carcinoma Therapy;International Journal of Molecular Sciences;2023-02-07

2. Interleukin 17 and Its Involvement in Renal Cell Carcinoma;Journal of Clinical Medicine;2022-08-24

3. Unique Growth Pattern Presentation of a Papillary Renal Cell Carcinoma;Diagnostics;2022-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3